Age Range: 18-80
Gender: Any

Study Description: This study is testing an investigational injectable medication for the treatment of Non-Alcoholic Steatohepatitis (NASH), newly known as Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis. Participants will receive either the study medication or a placebo as an injection, either weekly or bi-weekly, for 3 years. Additional procedures and tests will include vital signs, physical exams, laboratory tests, liver biopsies, FibroScans®and electrocardiograms (ECGs). Total participation will last approximately 3 years and 4 months, including 14 doctor’s visits and 4 phone visits throughout the study. Eligibility for the study will be determined by the study doctor following completion of all screening tests and procedures at an in-person screening visit to the clinic. Trial-related procedures and study medication will be provided at no cost.

Qualifications:
- Must be in stage 2, 3, or 4 Fibrosis
- Cannot have experienced significant weight gain or weight loss in the last 3 months (5% of body weight)
Qualifications:
- Cannot be diagnosed with asthma, lung fibrosis, pulmonary hypertension, interstitial lung disease, or sarcoidosis

PROOF REQUIRED

Mailer Access: Key: https://www.affiliateaccesskey.com/m-dzkm-s96-7b3bddaa5ec9115a077e95bf090d9865
Optout Link: https://www.twonailhall.com/o-dzkm-s96-bfc2ae7cf26f323c5398c1b008c6fabe